Literature DB >> 16376442

Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction.

Yoshitaka Ohashi1, Seinosuke Kawashima, Takao Mori, Mitsuyasu Terashima, Shinobu Ichikawa, Junya Ejiri, Kojiro Awano.   

Abstract

BACKGROUND: Inflammation, operated by blood, vascular and immune cells interaction, is implicated in plaque disruption and CD40 ligand (CD40L) was identified on activated T cells and platelets. We sought to investigate the roles of local inflammation in acute myocardial infarction (AMI).
METHODS: Coronary sinus (CS) and arterial (A) levels of interleukin (IL)-6 and soluble CD40L (sCD40L) and matrix metalloproteinase (MMP)-9 activity in serial blood samples obtained until 48 h after percutaneous coronary intervention (PCI) were determined. In tissue specimens obtained by aspirating thrombectomy and directional coronary atherectomy, CD40L was immunohistochemically stained.
RESULTS: Trans-cardiac gradient (CS-A) of IL-6, indicating cardiac release into the coronary circulation, significantly increased at 24 h after PCI in patients with AMI (group MI, n=17) in contrast with angina pectoris (n=10). Soluble CD40L levels in CS showed earlier peak, yielding trans-cardiac gradient, at 9 h in both groups. The maximum (max) release of IL-6 in MI, but not sCD40L, positively correlated with end-diastolic volume index (R=0.84) and negatively with ejection fraction (R=-0.66) by contrast ventriculography at 6-month follow up. Immunohistological study revealed the expression of CD40L in intra-coronary occlusive and mural thrombi. Aspirating thrombectomy significantly reduced the increase in both sCD40L levels and MMP-9 activity, but not max IL-6 release in MI.
CONCLUSIONS: In contrast with myocardial injury represented by IL-6 release, acute rise in sCD40L levels with the MMP-9 activation in the coronary circulation may possibly reflect local inflammation with platelet activation and be a novel marker of plaque damage by PCI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16376442     DOI: 10.1016/j.ijcard.2005.09.051

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Multivessel versus culprit-only revascularization: one time versus staged procedures for the ACS population.

Authors:  Pablo Codner; Ran Kornowski
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

2.  The effect of hormone therapy and tibolone on serum CD40L and ADAM-8 in healthy post-menopausal women.

Authors:  I Lambrinoudaki; M Karaflou; G Kaparos; O Grigoriou; A Alexandrou; C Panoulis; E Logothetis; M Creatsa; G Christodoulakos; E Kouskouni
Journal:  J Endocrinol Invest       Date:  2010-04-30       Impact factor: 4.256

3.  The roles of buyang huanwu decoction in anti-inflammation, antioxidation and regulation of lipid metabolism in rats with myocardial ischemia.

Authors:  Yu Liu; Rong Lin; Xiaolian Shi; Zhiyuan Fang; Weirong Wang; Qinqin Lin; Jiye Zhang; Hui Zhang; Qiaoli Ji
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-10       Impact factor: 2.629

4.  "One-Time" versus Staged Multivessel Intervention in Intermediate to Very High-Risk Patients with Non-ST-Segment Elevation Acute Coronary Syndromes.

Authors:  Xiaofan Yu; Yi Li; Qiancheng Wang; Ming Liang; Kai Xu; Yaling Han
Journal:  Korean Circ J       Date:  2016-11-01       Impact factor: 3.243

Review 5.  Staged versus One-Time Complete Revascularization with Percutaneous Coronary Intervention in STEMI Patients with Multivessel Disease: A Systematic Review and Meta-Analysis.

Authors:  Zhenwei Li; Yijiang Zhou; Qingqing Xu; Xiaomin Chen
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

Review 6.  Percutaneous coronary intervention in treatment of multivessel coronary artery disease in patients with non-ST-segment elevation acute coronary syndrome.

Authors:  Paweł Gąsior; Piotr Desperak; Karolina Gierlaszyńska; Michał Hawranek; Marek Gierlotka; Mariusz Gąsior; Lech Poloński
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-06-17       Impact factor: 1.426

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.